AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01675791 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALK tree AIT 1 DU
Study NCT01675791 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALK tree AIT 2 DU
Study NCT01675791 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALK tree AIT 4 DU
Study NCT01675791 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALK tree AIT 7 DU
Study NCT01675791 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALK tree AIT 12 DU
Study NCT01675791 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: ALK tree AIT Placebo
Study NCT02564549 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TRUS-guided biopsy
Description: Patients on the TRUS biopsy-based arm will undergo annual systematic biopsies without any MRI staging or guidance.
Study NCT02564549 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mpMRI with targeted biopsy
Description: Patients on the mpMRI- based arm will undergo annual mpMRI surveillance imaging, with image-guided targeted biopsies only as indicated by radiographic findings.
Study NCT00660699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT00660699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study NCT00660699 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Study NCT01603316 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: surveys
Description: Each survey will take about 45 minutes.Surveys will include questions on medical treatment, health insurance, work-related information, overall health and well being, eating habits, and satisfaction/use of the food program provided. 3 and 6-month follow-up. All participants will be asked to complete the study contact form. Need Assessment surveys will be administered via telephone or in person. The content of the needs assessment questionnaire has been informed by themes generated through IHCD's ongoing research and community outreach and service activities with the cancer patient population at our participating institutions. The survey will ask participants about the impact on their cancer care and their socioeconomic needs of the COVID-19 crisis.
Study NCT01603316 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: surveys
Description: Each survey will take about 45 minutes.Surveys will include questions on medical treatment, health insurance, work-related information, overall health and well being, eating habits, and satisfaction/use of the food program provided. 3 and 6-month follow-up. All participants will be asked to complete the study contact form. Need Assessment surveys will be administered via telephone or in person. The content of the needs assessment questionnaire has been informed by themes generated through IHCD's ongoing research and community outreach and service activities with the cancer patient population at our participating institutions. The survey will ask participants about the impact on their cancer care and their socioeconomic needs of the COVID-19 crisis.
Study NCT01603316 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Focus groups
Description: Prior to conducting the updated RCT design with the expanded cohort, we will conduct 4-6 focus groups (to saturation) with underserved breast cancer patients to optimally tailor the written materials, via mail, MSK Secure email, or in person and nutrition education sessions.
Study NCT01603316 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focus groups
Description: Prior to conducting the updated RCT design with the expanded cohort, we will conduct 4-6 focus groups (to saturation) with underserved breast cancer patients to optimally tailor the written materials, via mail, MSK Secure email, or in person and nutrition education sessions.
Study NCT00926055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetrol (Ezetimibe)
Description: Ezetrol - 10 mg once daily for 3 months
Study NCT00926055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vytorin (Ezetimibe + Simvastatin)
Description: Vytorin - 10/20 mg once daily for 3 months
Study NCT02932475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 1000 mg twice a day
Study NCT02932475 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Delivered to match active drug
Study NCT04586894 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: Gadolinium-enhanced magnetic resonance imaging of the heart before the first cycle of chemotherapy
Study NCT04586894 — intervention group
Intervention type: DEVICE
Intervention: Smart cloth
Description: A smart cloth recording cardiac and hemodynamic parameters will be worn by patients during 42 days. Replaced by a holter monitor if the smart cloth is refused or not tolerated by the patient.
Study NCT04586894 — intervention group
Intervention type: OTHER
Intervention: Biobanking
Description: Blood samples (plasma, serum, DNA, stem cells, immune cells) taken as part of the study will be stored in a biological sample collection. These samples may be used for further analysis not described in the initial protocol but which may be useful for investigation or in light of advances in scientific knowledge.
Study NCT00112099 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery: Splenectomy
Description: Procedure/Surgery: Surgery: Splenectomy
Study NCT00112099 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery: Spleen-preservation
Description: Procedure/Surgery: Surgery: Spleen-preservation
Study NCT01399801 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Doppler flow measurement
Description: use of doppler wire to measure change in flow that corresponds to changes in stroke volume to guide LV lead placement
Study NCT01399801 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard implantation of the LV lead
Description: Standard implantation of the LV lead with measurements of flow
Study NCT01031524 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfCS102
Description: Antigen of the sporozoite protein
Study NCT01031524 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Montanide ISA 720
Description: adjuvant alone
Study NCT02923596 — intervention group
Intervention type: PROCEDURE
Intervention: History of prior Surgery
Description: History of prior Surgery will be reviewed
Study NCT02923596 — intervention group
Intervention type: RADIATION
Intervention: History of Radiation Therapy
Description: History of prior radiation therapy will be reviewed
Study NCT03105583 — intervention group
Intervention type: DRUG
Intervention: Medication use during pregnancy
Study NCT03105583 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Supplement use during pregnancy
Study NCT03105583 — intervention group
Intervention type: OTHER
Intervention: Vitamin status of a pregnant woman
Description: Haemoglobin, RBC count + hematocrits, thrombocytes count, folate (serum), vitamin B12, WBC count, ferritin, iron (serum), transferrin % and saturation, TSH, T4, free glucose, LDH, ALT, AST, GGT, bilirubin (total), CRP, albumin, total protein, ureum, uric acid, creating, calcium (total), 25-hydroxy vitamin D, Na, K, Mg
Study NCT00876421 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo / 12 weeks
Study NCT00876421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine
Description: 4mg / 12 weeks
Study NCT00876421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-8539
Description: low dose / 12 weeks
Study NCT00876421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-8539
Description: medium dose / 12 weeks
Study NCT00876421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-8539
Description: higher dose / 12 weeks
Study NCT00413400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: 50 mg one syringe sc 2X per week for three months followed by 50 mg one syringe sc 1X per week for three months
Study NCT00413400 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 mg one syringe sc 2x per week for three months followed by 50 mg one syringe sc 1X per week for three months
Study NCT01297556 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy(CBT)
Description: Cognitive Behavior Therapy(CBT) for 6 weeks.
Study NCT03905408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mL of 50% Glucose
Description: 1st dose
Study NCT03905408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mL of 50% Glucose
Description: 2nd dose
Study NCT03905408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150 mL of 50% Glucose
Description: 3rd dose
Study NCT03905408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mL of 50% Glucose
Description: 4th dose
Study NCT00121381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimecrolimus plus topical corticosteroid (TCS)
Description: Pimecrolimus 1 % cream plus topical corticosteroid (TCS) twice daily
Study NCT00121381 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS)
Description: twice daily administration
Study NCT01748266 — intervention group
Intervention type: OTHER
Intervention: microcirculatory reactivity
Description: Microcirculation of the thenar eminence was analyzed by NIRS technology, through the StO2 and the resaturation slope after an ischemic challenge.
Study NCT03319173 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention
Description: Subjects in the experimental group will receive clinically regulated meal plans designed to facilitate prolonged benign dietary ketosis (BDK) in order to regulate glucose with restored insulin sensitivity focused at reversing the impaired capacity to switch between fat and carbohydrate oxidation.~Subjects in the control group will follow the their current dietary protocol (Standard American Diet-SAD).
Study NCT03319173 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Subjects in the experimental group will receive clinically regulated meal plans designed to facilitate prolonged benign dietary ketosis (BDK) in order to regulate glucose with restored insulin sensitivity focused at reversing the impaired capacity to switch between fat and carbohydrate oxidation.~Subjects in the control group will follow the their current dietary protocol (Standard American Diet-SAD).
Study NCT00522015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rivastigmine
Description: rivastigmine 6 mg up to 12 mg daily; Taken in two doses from 3 mg to 6 mg Rivastigmine twice a day
Study NCT03507231 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Email Message
Description: Participants will randomly receive an e-mail message about the availability of free flu vaccines.
Study NCT03507231 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Email Message
Description: Participants will randomly receive an e-mail message about the availability of free flu vaccines.
Study NCT03381924 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational programme
Description: In each session, neuroscience-based information on the neurophysiology of pain and migraine were provided with audio-visual support.
Study NCT03507231 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentive for Vaccination
Description: $5 gift card offered for vaccination
Study NCT03507231 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentive for completing a short survey
Description: $5 gift card offered for completing s short survey after one gets vaccinated
Study NCT03428932 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed Loop (Medtronic 670G)
Description: A loaner Medtronic 670G insulin pump, Enlite 3 sensor and GST3C Guardian transmitter will be utilized
Study NCT03428932 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Subjects will continue on their current treatment (insulin pump or injections), with follow up every 3 months.
Study NCT04027543 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Neoadjuvant chemoradiotherapy
Description: In most patients, the chemotherapy regimens before surgery were consisted of cisplatin combined with either fluorouracil or taxanes.
Study NCT04027543 — intervention group
Intervention type: PROCEDURE
Intervention: Oesophagectomy
Description: Various surgical oesophagectomy methods were used, such as Ivor Lewis, transthoracic, three-hole, transhiatal, and left transthoracic,and the appropriate surgical approach for each patient was chosen according to the tumour location, size, and depth.
Study NCT04027543 — intervention group
Intervention type: DRUG
Intervention: Neoadjuvant chemotherapy
Description: In most patients, the chemotherapy regimens before surgery were consisted of cisplatin combined with either fluorouracil or taxanes.
Study NCT03652168 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: 10 minute a day, 8 week digital meditation
Study NCT01754870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine and Rituximab Induction followed by Rituximab and Lenalidomide Maintenance
Study NCT00074269 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Study NCT00074269 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00074269 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: graft-versus-tumor induction therapy
Study NCT00074269 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes
Study NCT00074269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Study NCT00074269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Study NCT00074269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Study NCT00074269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study NCT00074269 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT02633605 — intervention group
Intervention type: DEVICE
Intervention: First Sense Medical®
Study NCT01509092 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vitrectomy surgery
Description: pars plana vitrectomy +internal limiting membrane peeling done immediately after the identification of the macular hole
Study NCT03803995 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mapping and Pacing the His Bundle
Description: During the device implant procedure, 3D electro-anatomical mapping of the His Bundle region will be performed using EnSite™ Precision™ mapping system and Advisor™ HD Grid mapping catheter. This procedure might be part of the standard-of-care at the participating centers.
Study NCT03803995 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Placing a guidewire in Coronary sinus for measurement of Q-LV during His Bundle pacing or, if needed, for LV pacing
Description: During the device implant procedure, a VisionWire coronary guidewire will also be placed into a branch of coronary sinus (CS), targeting a lateral branch. This guidewire could be used for collecting local left ventricle (LV) activation time (Q-LV) or pacing the LV. This guidewire could also be used to deliver a LV lead at physician's discretion. This procedure might be part of the standard-of-care at the participating centers.
Study NCT04227990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, doxorubicin, and cyclophosphamide (TAC)
Description: Docetaxel is a type of chemotherapy medicine called an taxane. Doxorubicin is a type of chemotherapy medicine called an anthracycline. Cyclophosphamide is a type of chemotherapy medicine called an alkylating agent.
Study NCT04227990 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel, doxorubicin, and cyclophosphamide (TAC)
Description: Docetaxel is a type of chemotherapy medicine called an taxane. Doxorubicin is a type of chemotherapy medicine called an anthracycline. Cyclophosphamide is a type of chemotherapy medicine called an alkylating agent.
Study NCT03381924 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Routine clinical practice
Description: Patients allocated to the control group will only receive the drugs used in the habitual clinical practice
Study NCT01228071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone gel 2%
Description: 40 mg testosterone gel 2%
Study NCT04140708 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise--Rock Steady Boxing class
Description: Rock Steady Boxing is a class designed specifically for those with Parkinsonism and movement difficulty using explosive and fine tuned movements as well as cognitive learning skills.
Study NCT00924976 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Steps for Achieving Financial Empowerment (SAFE)
Description: The SAFE is a brief, 5-component intervention that aims to facilitate a cooperative consumer-payee relationship, increase accurate knowledge about representative payeeship, promote collaborative money management and effective budgeting, and prepare mutually developed plans for carrying out the payeeship in the future.
Study NCT04548089 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful-Compassion Art Therapy for Dementia Care (MCAT-DC)
Description: Each Mindful-Compassion Art Therapy for Dementia Care (MCAT-DC) will focus on 3 major areas that cultivate self-care, resilience and communal support. The specific intervention structure include: Week 1 - Empowering Self-Care: Introduction to the science of stress, self-care, burnout, as well as the arts and mindfulness to cultivate resilience; Week 2 - Reflective Caregiving: Reflection of caregiving experiences that demonstrates strengths and challenges; Week 3 - Understanding Loss: Introduction to the science of loss, how grief can impair hope and wellbeing, and how self-compassion can help transform suffering into blessings.; Week 4 - Meaning Reconstruction: Reflection on caregiver identities, to elicit the lessons and wisdoms learnt, and to create renewed meaning to sustain their caregiving journeys. Guided mindfulness mediation will also be professionally recorded to form a daily take-home mindfulness mediation exercise for participants, each exercise will last 10-20 minutes.
Study NCT02150824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: BI 187004 high dose matching placebo once daily
Study NCT02926859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol as add-on
Description: Cannabidiol capsules 2x200 mg twice a day as add-on to individualized pharmacological treatment with either amisulpride, aripiprazole, olanzapine, quetiapine or risperidone over 26 weeks
Study NCT02926859 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo as add-on
Description: Placebo capsules 2x200 mg twice a day as add-on to individualized pharmacological treatment with either amisulpride, aripiprazole, olanzapine, quetiapine or risperidone over 26 weeks
Study NCT02458729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid 5%,5ml/amp (intraoperative)
Description: tranexamic acid 1g administered intravenously five minutes before deflation of the tourniquet
Study NCT03175757 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Turmeric and Black Cumin Seed
Description: Turmeric and Black Cumin Seed formulation
Study NCT03175757 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03616275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HRV biofeedback
Description: HRV biofeedback protocol is modified from Lehrer's HRV biofeedback manual (2000), which had been successfully used to improve functioning and quality of life for patients with asthma and COPD. A noninvasive biofeedback system with a NeXus-10 with BioTrace+ (Mind Media B.V., Netherlands) and laptop computer will be used for biofeedback intervention. The intervention protocol is including paced breathing in resonant frequency, abdominal breathing and pursed-lip breathing, and visual biofeedback. The designed intervention protocol will include 8 once-a-week, individual, 20-min in hospital training sessions and twice-a-day, 20-min home self-practices.
Study NCT02086292 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2 ml 1% Lidocaine
Study NCT02086292 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1 ml 2% Lidocaine
Study NCT02053051 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABC4D
Description: Advanced Bolus Calculator for Type 1 Diabetes (ABC4D) to calculate pre-meal insulin boluses
Study NCT02053051 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard bolus calculator
Study NCT02138500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06372865
Description: Single, oral dose administration of 10 mg PF-06372865 using tablet formulation.
Study NCT02458729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid 5%,5ml/amp (3 hours after operation)
Description: tranexamic acid 1g administered intravenously 3 hours after operation
Study NCT02458729 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Normal Saline (intraoperative)
Description: 0.9% Normal Saline 20ml administered intravenously five minutes before deflation of the tourniquet